Activin and Inhibin

EL-102 is a hypoxia-induced factor 1 (Hif1α) inhibitor. EL-102 induces apoptosis , inhibits tubulin polymerisation and shows activities against prostate cancer . EL-102 can be used for the research of cancerIn VitroEL-102 (0-120 nM: 72 h) inhibits

EL-102 is a hypoxia-induced factor 1 (Hif1α) inhibitor. EL-102 induces apoptosis , inhibits tubulin polymerisation and shows activities against prostate cancer . EL-102 can be used for the research of cancerIn VitroEL-102 (0-120 nM: 72 h) inhibits

EL-102 is a hypoxia-induced factor 1 (Hif1α) inhibitor. EL-102 induces apoptosis , inhibits tubulin polymerisation and shows activities against prostate cancer . EL-102 can be used for the research of cancerIn VitroEL-102 (0-120 nM: 72 h) inhibits

EL-102 is a hypoxia-induced factor 1 (Hif1α) inhibitor. EL-102 induces apoptosis , inhibits tubulin polymerisation and shows activities against prostate cancer . EL-102 can be used for the research of cancerIn VitroEL-102 (0-120 nM: 72 h) inhibits

ELA-32(human) TFA is a potent, high affinity apelin receptor agonist (IC 50 =0.27 nM: K d =0.51 nM). ELA-32(human) TFA exhibits no binding GPR15 and GPR25. ELA-32(human) TFA activates the PI3K/AKT pathway and promotes self-renewal of hESCs via

ELA-32(human) TFA is a potent, high affinity apelin receptor agonist (IC 50 =0.27 nM: K d =0.51 nM). ELA-32(human) TFA exhibits no binding GPR15 and GPR25. ELA-32(human) TFA activates the PI3K/AKT pathway and promotes self-renewal of hESCs via

ELA-32(human) TFA is a potent, high affinity apelin receptor agonist (IC 50 =0.27 nM: K d =0.51 nM). ELA-32(human) TFA exhibits no binding GPR15 and GPR25. ELA-32(human) TFA activates the PI3K/AKT pathway and promotes self-renewal of hESCs via

ELA-32(human) TFA is a potent, high affinity apelin receptor agonist (IC 50 =0.27 nM: K d =0.51 nM). ELA-32(human) TFA exhibits no binding GPR15 and GPR25. ELA-32(human) TFA activates the PI3K/AKT pathway and promotes self-renewal of hESCs via

Eleclazine (GS 6615) hydrochloride is a selective cardiac late sodium current inhibitor and a weak inhibitor of potassium current with IC 50 value of &lt:1 μM and approximately 14.2 μM, respectively. Eleclazine hydrochloride shows concurrent

Eleclazine (GS 6615) hydrochloride is a selective cardiac late sodium current inhibitor and a weak inhibitor of potassium current with IC 50 value of &lt:1 μM and approximately 14.2 μM, respectively. Eleclazine hydrochloride shows concurrent

Eleclazine (GS 6615) hydrochloride is a selective cardiac late sodium current inhibitor and a weak inhibitor of potassium current with IC 50 value of &lt:1 μM and approximately 14.2 μM, respectively. Eleclazine hydrochloride shows concurrent

Eleclazine (GS 6615) hydrochloride is a selective cardiac late sodium current inhibitor and a weak inhibitor of potassium current with IC 50 value of &lt:1 μM and approximately 14.2 μM, respectively. Eleclazine hydrochloride shows concurrent